HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript
HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript
Seeking Alpha8/14/2026Neutral
HTFL
Heartflow, Inc. Common StockNASDAQHEALTHCAREHEALTH INFORMATION SERVICES
Key Statistics
Market Cap
$3.65B
P/E Ratio
—
EPS
$-3.15
Beta
—
52W High
$43.28
52W Low
$20.13
50-Day MA
$28.99
200-Day MA
$28.85
Dividend Yield
—
Profit Margin
-55.80%
Forward P/E
—
PEG Ratio
—
About Heartflow, Inc. Common Stock
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases globally. The company is headquartered in Mountain View, California.
Fundamentals
| Revenue (TTM) | $212.07M |
| Gross Profit (TTM) | $169.83M |
| EBITDA | $-71.36M |
| Operating Margin | -27.90% |
| Return on Equity | -154.20% |
| Return on Assets | -18.10% |
| Revenue/Share (TTM) | $2.76 |
| Book Value | $3.23 |
| Price-to-Book | 13.08 |
| Price-to-Sales (TTM) | 17.20 |
| EV/Revenue | 16.61 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 47.60% |
| Shares Outstanding | $86.95M |
| Float | $66.98M |
| % Insiders | 5.21% |
| % Institutions | 91.32% |
Historical Volatility
HV 10-Day
148.46%
HV 20-Day
113.39%
HV 30-Day
102.72%
HV 60-Day
91.42%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($43.50 target)
2
Strong Buy6
Buy1
HoldLatest News
Heartflow Q2 Earnings Call Highlights
Heartflow NASDAQ: HTFL reported second-quarter revenue of $64.1 million, up 48% from a year earlier, as growth in its Plaque Analysis offering, durable FFR-CT utilization and continued expansion of the coronary CT angiography, or CCTA, market supported results.
MarketBeat8/14/2026Positive
Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended June 30, 2026.
GlobeNewsWire8/13/2026Neutral
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
Heartflow Plaque Staging TM , the only staging tool based on total plaque volume * , is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproducibility and utility of Heartflow Plaque Analysis SAN FRANCISCO, July 09, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced eight new datasets from clinical studies spanning more than 36,000 patients will be presented at the Society of Cardiovascular Computed Tomography (SCCT) 2026 Annual Scientific Meeting taking place July 9-12, 2026 in San Diego. These studies reveal over 50% of symptomatic patients with zero coronary artery calcium (CAC) harbor significant non-calcified plaque that traditional CAC scoring cannot detect.
GlobeNewsWire7/9/2026Neutral
Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026.
GlobeNewsWire5/14/2026Neutral
Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026
SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market close on Thursday, May 14, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 14, 2026.
GlobeNewsWire4/23/2026Neutral
Heartflow Files Patent Infringement Lawsuit Against Cleerly
Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform
GlobeNewsWire4/13/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HTFL and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026